Nano Delivery System for Atherosclerosis DOI Creative Commons
Rong Zhang,

Xuan He,

T. Y. Fan

и другие.

Journal of Functional Biomaterials, Год журнала: 2024, Номер 16(1), С. 2 - 2

Опубликована: Дек. 24, 2024

Atherosclerosis, a pathological process propelled by inflammatory mediators and lipids, is principal contributor to cardiovascular disease incidents. Currently, drug therapy, the primary therapeutic strategy for atherosclerosis, faces challenges such as poor stability significant side effects. The advent of nanomaterials has garnered considerable attention from scientific researchers. Nanoparticles, liposomes polymeric nanoparticles, have been developed delivery in atherosclerosis treatment. This review will focus on how nanoparticles effectively improve safety efficacy, well continuous development optimization same material further explore current future opportunities this field.

Язык: Английский

Role of PEGylated lipid in lipid nanoparticle formulation for in vitro and in vivo delivery of mRNA vaccines DOI
Li Zhang,

Brandon Yi Loong Seow,

K Ba

и другие.

Journal of Controlled Release, Год журнала: 2025, Номер 380, С. 108 - 124

Опубликована: Фев. 5, 2025

Язык: Английский

Процитировано

1

Advances in Lipid Nanoparticle‐Based Disease Treatment DOI Open Access
Yujie Zhou,

Qiqi Ge,

Xin Wang

и другие.

ChemMedChem, Год журнала: 2025, Номер unknown

Опубликована: Фев. 17, 2025

Abstract Lipid nanoparticles (LNPs) have emerged as a transformative platform for the targeted delivery of therapeutic agents, revolutionizing treatment paradigms across spectrum diseases. Since inception liposomes in 1960s, lipid‐based nanotechnology has evolved to address limitations such poor bioavailability, off‐target effects, and instability, thereby enhancing efficacy safety drug administration. This review highlights latest advancements LNPs technology, focusing on their application cancer therapy, gene infectious disease management, glaucoma, other clinical areas. Recent studies underscore potential deliver messenger RNA (mRNA) small interfering (siRNA) precise genetic intervention, exemplified by breakthroughs interference CRISPR‐Cas9 genome editing. Additionally, been successfully employed ameliorate conditions, demonstrating versatility addressing both acute chronic disorders. However, challenges persist concerning large‐scale manufacturing, long‐term stability, comprehensive evaluations. Future research must focus optimizing formulations, exploring synergistic combinations with existing therapies, expanding scope treatable The integration into personalized medicine exploration applications diseases represent promising avenues further investigation. are poised play an increasingly central role development next‐generation therapeutics.

Язык: Английский

Процитировано

1

Comprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery DOI Creative Commons
Md. Anamul Haque, Archana Shrestha, Constantinos M. Mikelis

и другие.

International Journal of Pharmaceutics X, Год журнала: 2024, Номер 8, С. 100283 - 100283

Опубликована: Сен. 10, 2024

Язык: Английский

Процитировано

6

Lipid nanoparticle (LNP) mediated mRNA delivery in neurodegenerative diseases DOI

Seyedeh Ghazal Moosavi,

Niloufar Rahiman, Mahmoud Reza Jaafari

и другие.

Journal of Controlled Release, Год журнала: 2025, Номер unknown, С. 113641 - 113641

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0

The Fomivirsen, Patisiran, and Givosiran Odyssey: How the Success Stories May Pave the Way for Future Clinical Translation of Nucleic Acid Drugs DOI
Mona Mansouri,

Kimia Mansouri,

Zahra Taheri

и другие.

BioDrugs, Год журнала: 2025, Номер unknown

Опубликована: Апрель 5, 2025

Язык: Английский

Процитировано

0

Engineering innate immune cells for cancer immunotherapy DOI
Mubin Tarannum,

Xizhong Ding,

Marta Barisa

и другие.

Nature Biotechnology, Год журнала: 2025, Номер 43(4), С. 516 - 533

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0

New insights into diabetes-induced cardiac pathology DOI
Kate L. Weeks, Bianca C. Bernardo, James R. Bell

и другие.

Journal of Molecular and Cellular Cardiology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0

In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy DOI Creative Commons
Weiyue Zhang, Xin Huang

Journal of Hematology & Oncology, Год журнала: 2024, Номер 17(1)

Опубликована: Ноя. 13, 2024

Chimeric antigen receptor (CAR) cell therapy has achieved groundbreaking success in treating hematological malignancies. However, its application to solid tumors remains challenging due complex manufacturing processes, limited vivo persistence, and transient therapeutic effects. In CAR-immune cells induced by gene delivery systems loaded with CAR genes gene-editing tools have shown efficiency for anti-tumor immunotherapy. situ programming of autologous immune avoids the safety concerns allogeneic cells, manufacture could be standardized. Therefore, editing generation might potentially overcome abovementioned limitations current therapy. This review mainly focuses on structures, tools, techniques applied immunotherapy help design develop The recent applications both hematologic malignancies are investigated. To sum up, holds promise offering a practical, cost-effective, efficient, safe, widely applicable approach next-generation

Язык: Английский

Процитировано

2

The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems DOI Creative Commons
Nargish Parvin, Tapas Kumar Mandal, Sang‐Woo Joo

и другие.

Pharmaceutics, Год журнала: 2024, Номер 16(11), С. 1366 - 1366

Опубликована: Окт. 25, 2024

The COVID-19 pandemic has significantly accelerated progress in RNA-based therapeutics, particularly through the successful development and global rollout of mRNA vaccines. This review delves into transformative impact on RNA with a strong focus lipid nanoparticles (LNPs) as pivotal delivery platform. LNPs have proven to be critical enhancing stability, bioavailability, targeted mRNA, facilitating unprecedented success vaccines like those developed by Pfizer-BioNTech Moderna. Beyond vaccines, LNP technology is being explored for broader therapeutic applications, including treatments cancer, rare genetic disorders, infectious diseases. also discusses emerging systems, such polymeric viral vectors, which offer alternative strategies overcome existing challenges related immune responses, tissue-specific targeting. Additionally, we examine pandemic's influence regulatory processes, fast-tracked approvals therapies, surge research funding that spurred further innovation field. Public acceptance grown, laying groundwork future developments personalized medicine. By providing an in-depth analysis these advancements, this highlights long-term evolution therapeutics precision drug technologies.

Язык: Английский

Процитировано

1

Nano Delivery System for Atherosclerosis DOI Creative Commons
Rong Zhang,

Xuan He,

T. Y. Fan

и другие.

Journal of Functional Biomaterials, Год журнала: 2024, Номер 16(1), С. 2 - 2

Опубликована: Дек. 24, 2024

Atherosclerosis, a pathological process propelled by inflammatory mediators and lipids, is principal contributor to cardiovascular disease incidents. Currently, drug therapy, the primary therapeutic strategy for atherosclerosis, faces challenges such as poor stability significant side effects. The advent of nanomaterials has garnered considerable attention from scientific researchers. Nanoparticles, liposomes polymeric nanoparticles, have been developed delivery in atherosclerosis treatment. This review will focus on how nanoparticles effectively improve safety efficacy, well continuous development optimization same material further explore current future opportunities this field.

Язык: Английский

Процитировано

1